Navigation Links
Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results from the Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positive clinical profile of the Endeavor(R) drug-eluting coronary stent and bring to nearly 1,300 the number of Endeavor patients who have at least two years of follow-up. Significantly, among those 1,300 Endeavor patients, there have been no reported cases of late stent thrombosis using the independent, pre-specified clinical trial protocol definitions for thrombosis. The results were presented today during the 56th Annual Scientific Session of the American College of Cardiology (ACC) conference in New Orleans.

Those in the 436-patient ENDEAVOR III trial are being followed out to five years. The clinical data reported at ACC as part of the study design indicate that the Endeavor stent continues to exhibit an excellent safety profile while delivering sustained efficacy and a low need for repeat procedures that is consistent with the overall Endeavor clinical program. At two years, the rate of Major Adverse Cardiac Events - a composite safety measure of death, repeat procedures and myocardial infarction (MI) - was reported to be 9.3% for Endeavor and 11.6% for the Cypher stent also studied in the ENDEAVOR III trial (p = 0.47). There was no statistically significant difference in the need for repeat procedures, or Target Lesion Revascularization (7.0% and 4.5% for Endeavor and Cypher, respectively, p = 0.50), or all-cause mortality (1.6% for Endeavor and 4.5% for Cypher, p = 0.14). However, fewer patients experienced heart attacks (MI) when treated with the Endeavor stent (0.6% vs. 3.6% for Cypher, p = 0.04) and the combined rate of heart attack and death also was statistically significantly lower among patients randomized to the Endeavor stent (2.2% vs. 7.1% for Cypher, p = 0.013).

Confidence in Endeavor safety

Worldwide, Medtronic has approximately 2,100 Endeavor patients enr
'"/>




Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
(Date:5/20/2013)... (PRWEB) May 20, 2013 According to a ... Warnings at Indoor Tanning Salons,” tanning salons in ... The Food and Drug Administration wants to see cancer warnings ... a minimum age floor of eighteen for the use of ... concerns about melanoma, which has become increasingly common over the ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, ... amount to approximately $3.6 billion dollars per year (i). ... estimated that there 15 million incidents of medical harm ... everyone who receives any form of medical treatment should ... Merriam-Webster defines malpractice as “a dereliction of professional duty ...
(Date:5/20/2013)... Osborn’s Brain: Imaging, Pathology, and ... Osborn’s 1993 award winning book Diagnostic Neuroradiology (a.k.a. “The ... neuroradiology texts. , In this highly anticipated 1,300-page ... complex topics visually appealing and easy to understand. It ... with spectacular pathology examples, relevant anatomy, and the most ...
(Date:5/20/2013)... Galveston researchers have been awarded a five-year, $1.8 million ... Stroke to apply the techniques of gene therapy to ... that arises from a malfunction in the nervous system. ... millions of Americans, manifesting itself in a variety of ... intense discomfort in response to a light touch, for ...
(Date:5/20/2013)... 20, 2013 Horizon NJ Health, New ... announced that it has earned a Commendable Accreditation ... Horizon NJ Health is a wholly owned subsidiary of ... , NCQA Health Plan Accreditation is a nationally recognized ... that health plans provide to their members. Health Plan ...
Breaking Medicine News(10 mins):Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... HIV positive girls will participate ,A beauty contest with ... 2005, which is the World AIDS Day, in which only ... ‘Miss Positive-2005’. The object of the contest is to change ... and also help HIV infected people lead a normal life. ...
... to two genes, both variant forms of a gene called ... in the smoking addiction.// The protein product of these genes ... the body. ,The two identified gene forms are ... metabolism of nicotine, more specifically found to account for slow ...
... heart failure patients in United States have better short-term ... over time.// ,Their study findings appear in the ... ,Heart failure is the most common cause of hospitalization ... ,The authors compared process of care and 30-day ...
... effective treatment option for patients with liver cancer. A ... to treat a patient who harbors a liver tumor ... surgical options are currently available for this group of ... the researchers who have now suggested a novel plan ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
... (QBI) have now found a process that could lead ... and acquired brain injury. ,The research focuses on ... memory function and where the brain's ability to regenerate ... ,The study by Dr Natalie Bull and Professor ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2Health News:Research Targets treatment for dementia and brain injuries 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medicine Products: